Abstract-In many parkinsonian syndromes, neuromelanin (NM)-containing dopaminergic neurons of the substantia nigra (SN) are selectively targeted by the noxius pathogens. Studies of the constitutional and functional features of human NM allow the formulation of a logical hypothesis on its role in parkinsonian syndromes. In the early stages, NM synthesis and iron-chelating properties may act as a powerful protective mechanism, delaying symptom appearance and/or slowing disease progression. Once these systems have been exhausted, the pathogenic mechanisms affecting cytoplasmic organelles other than NM destroy NM-harboring neurons, with consequent pouring out of NM granules. These in turn activate microglia, causing release of nitric oxide, interleukin-6 and tumor necrosis factor-␣, thus becoming an important determinant of disease aggravation. Neuromelanin appears to be a suitable target for devising chemical agents that might modify the course of these diseases. 
In 1783, Sir James Parkinson described the cardinal clinical features of the syndrome he named shaking palsy. Lewy, in 1912, reported the intracytoplasmic eosinophilic inclusions that bear his name, whose presence, together with a discoloration of the substantia nigra (SN) of Sommering, allows the pathologic identification of Parkinson's disease (PD). In the early sixties, Hornykiewicz and his collaborators elegantly demonstrated that loss of dopamine (DA) in the neostriatum was the biochemical landmark of PD and that exogenous supply of the DA precursor could temporarily reverse all major motor symptoms of the disease. 1, 2 In 1983, Langston's ingenuous clinical acumen related the sudden appearance of PD to an exogenous poisoning with a synthetic heroin analogue now known as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). 3 On the basis of that observation, an almost ideal animal model of PD has become available for the study of molecular mechanisms of selective degeneration of DA neurons in the SN of several animal species, including primates. In 1997, Polymeropoulos for the first time linked a genetic defect to familial PD. 4 These remarkable achievements have made PD the best understood neurodegenerative disorder compared to tauopathies, Alzheimer disease, amyotrophic lateral sclerosis, Huntington disease, and spinocerebellar atrophies, just to name the epidemiologically most relevant ones. Moreover, in terms of treatment no other neurodegenerative condition offers such effective and, to some extent, diversified treatment options, both pharmacologic and interventional. As a result, the next more ambitious goal, i.e., finding disease-modifying agents, becomes a more realistic hope for PD. To make this goal realistic, the key pathogenic elements must be identified as suitable targets amenable to interventional manipulation.
In the past several decades, clinical experience and advances in neurobiology have demonstrated that several other neurodegenerative conditions present typical parkinsonian symptoms and that several clinical patterns initially presenting with the classical triad of tremor, rigidity, and akinesia will develop symptoms and signs of involvement of other systems in addition to the nigrostriatal ascending dopaminergic pathway. Such syndromes encompass a wide variety of clinical conditions, usually referred to as parkinsonian syndrome (PS), and present substantial variations in their clinical course and, at some point, lack of response to dopaminergic treatments.
Several etiologies have been discovered for PD, such as xenobiotics (Mn, CO, MPTP), 5 genetic, infectious (Von Economo encephalitis), and iatrogenic (DA antagonists, Ca channel blockers). However, clinical experience has demonstrated that even within the same etiologic group of PS, as well as in typical PD itself, the course of the disease may be quite different, ranging from slowly smoldering forms to more malignant rapidly progressive ones. Here we propose one pathogenic mechanism that in itself may act as a protector in the initial phase of the disease and as a determinant of aggressiveness in the later stages.
The hypothesis is based on data from examination of postmortem material from normal and parkinsonian subjects and on experimental findings suggesting that an interplay between neuromelanin (NM) and iron in the SN is a key element in determining neuron death. If the suggested theory holds true NM can become a suitable target for diseasemodifying agents, in PD and other PS in which pigmented dopaminergic neurons in the SN are selectively affected.
Neuromelanin: structure, synthesis, and function. NM is a pigment found only in specific areas of the CNS of mammalian species, with a variable degree of concentration in the phylogenetic scale: highest in primates and humans. Two areas of the brainstem, the SN and the locus coeruleus (LC), contain proportionally the greatest amount of NM, which increases with age. 6 NM derives from the metabolism of catecholamines, DA for the SN and norepinephrine (NE) for the LC. NM synthesis appears to be driven by an excess of cytosolic catecholamines that are not accumulated into synaptic vesicles 7 by the synaptic vesicular monoamine transporter 2 (VMAT2), the concentration of which in regions of the human SN has been found to be inversely proportional to the amount of NM present (figure 1). 8 The exact final structure of NM is not known. However, it has a multilayered 3D structure in which each polymeric layer is composed of melanin groups bound to aliphatic chains and peptide moieties. In the melanic component are dihydroxyindole and benzothiazine rings and in its synthesis are involved DA-derived and cysteinildopamine-derived units of proteins. [9] [10] [11] [12] [13] These adducts are probably sequestered in autophagic organelles and processed to form the final NM. The NM organelles have a double membrane typical of autophagic vacuoles (see figure  1) . It is not clear whether NM synthesis is a multistep autoxidation process or is enzymatically controlled. The identification of DA-derived units as building blocks of NM suggests a detoxifying role of NM synthesis, thus preventing the intraneuronal accumulation of those compounds, which would be toxic. 7, 14 NM is likely related to lipofuscin because the two are always found together. [15] [16] [17] Although the ultimate role of NM is unknown, several of its functions have been identified. NM avidly binds to heavy metals, both physiologically present and exogenously administered. 18 Through the presence of the dihydroxyindole groups in its chemical structure, NM chelates a variety of metals (figure 2).
Particularly relevant to a putative role in the genesis of PD is the interaction between NM and iron. NM is the main molecule of iron deposits in the dopaminergic neurons of the SN. It should be emphasized that in these very same neurons L-ferritin levels are very low, and the two features may be intercorrelated. In PD an increase of total iron content in the SN has been found. There is also a spe- cific iron overload in NM at variance with normal subjects, in whom only 50% of the NM chelating ability is saturated. [19] [20] [21] Such an iron overload of NM is likely the consequence of an increase of iron concentration and of reactivity and mobilization from glia to neurons, where iron is scavenged by NM. Other types of metals can also be bound by NM, including endogenous metals in reactive form and therefore potentially toxic (Zn, Cu, Mn) and toxic metals deriving from environmental exposure (Cd, Hg). 18 A powerful antioxidant effect is exerted by NM by sequestering redox-active iron ions. 22 Such a highcapacity trapping defense system against toxic molecules has been imaginatively compared to a "black hole" beneficially at work against oxidative stress within the SN, a structure particularly vulnerable to such damaging agents. In this regard there is substantial evidence of a constitutional paucity of major enzymatic defense mechanisms against oxygen radicals, particularly the GSH 23 and ubiquinone 24 systems, which are further impaired in animal models of PD.
Parkinson-genic noxae such as 1-methyl-4-phenylpyridinium ion (MPP ϩ ), paraquat, and beta carbolines accumulate in NM granules. [25] [26] [27] PDinducing drugs, such as chlorpromazine and haloperidol, also bind avidly to NM. 28 On the other hand extraneuronal NM activates microglia which, in turn, phagocytoses extravasated granules and releases several powerful neurotoxic mediators: nitric oxide, interleukin-6, and tumor necrosis factor-␣ (figure 3).
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NM in aging and PD. The reasons for the variation of NM content in the SN are under debate. These changes may be the result of several factors. One is aging per se; if there is an age-related neuron loss in the SN (the issue is under debate), 30 this may affect pigmented or nonpigmented neurons preferentially. Another possibility is the differential neuronal vulnerability and consequent depletion of pigmented versus nonpigmented cells in PD. [31] [32] [33] [34] [35] [36] [37] [38] All these uncertainties notwithstanding, NM levels are consistently and significantly lower (about half the level of agematched controls) in postmortem material from parkinsonian patients 30 (for a discussion see ref. 39 ). Histologic studies have reported that, in PD, lightly melanized neurons are more vulnerable than heavily melanized ones. 36, 40, 41 The marked NM depletion that occurs in the SN of PD subjects might be regarded as a marker for early diagnosis of PD by development of adequate in vivo imaging methods, as reported in a recent pilot study employing ultrasound and showing a correlation between a hyperechogenic area of the SN and content of NM and iron. 42 A linear increase in NM concentration during aging, with levels similar to those measured in the SN, was also found in the LC. 6 There appears to be no direct correlation between the amount of NM present in a given SN neuron and its vulnerability to a parkinsongenic noxa. At any rate, in an acute parkinsonian condition in humans, 43 that induced by the xenobiotic MPTP, extraneuronal granules of NM have been seen in the SN surrounded by microglia, a finding already observed experimentally in primates (see figure 3) .
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NM as a putative mechanism of disease progression in PS. Our present knowledge regarding NM structure, function, and behavior in physiologic and pathologic aging allows the formulation of a logical hypothesis concerning the role of this molecule when a PS is developing. While at work, any Parkinson-genic noxa is believed to destroy neurons in the SN also through generation of free oxygen radicals. NM offers two potent antioxidant mechanisms. (a) Cytosolic catecholamines are trapped during NM synthesis, with the direct consequence of quenching DA metabolism, a powerful generator of ROS and potentially toxic condensation products with proteins ( figure 1). (b) The "black hole" function, sweeping metal ions off the cytosol and inactivating them within the NM structure, is beneficial, particularly for the trapping of iron, which is postulated to be a key pathogen in PD (see figure 2) . 45 This process enables NM-rich nigral neurons to sustain a much greater insult than those with no or little NM content. Therefore, in the early phases NM may act as a strong neuron protectant and a key factor in delaying neuron death and symptom appearance, which is believed to be manifested once at least 60% of nigral neurons have been depleted. 35 With disease advancement, the buffering capabilities of NM come to saturation and NM-containing neurons die as well. The ensuing extravasation of NM in granular form attracts and activates microglia, causing release of the above-mentioned neurotoxic molecules (nitric oxide, interleukin-6, and tumor necrosis factor-␣) (figure 3). NM can specifically reduce the activity of the 26S proteasome without affecting 20S proteasome activity in vitro. NM reduces the amount of the PA700 regulatory subunit of 26S proteasome, but does not affect that of alpha-and beta-subunits of the 20S proteasome. In pathologic conditions a leakage of NM from organelles could inhibit the 26S proteasome, causing accumulation of abnormal proteins, and might determine the selective vulnerability of DA neurons in aging and related disorders. 46 In each individual patient the intensity of the response will depend on the specific reactive propensity of these systems. This variable reactivity may become an important determinant of disease progression, explaining the wide variety of aggressiveness and speed of advancement of the disease process commonly observed in clinical practice. Therefore, in spite of common or different etiologic factors, the pathogenesis in several PS may be different in each patient and to a significant extent linked to the NM system. In addition, the NM system appears to be a suitable target for discovering innovative disease-modifying agents.
